Literature DB >> 9591958

Six-year supplementation with alpha-tocopherol and beta-carotene and age-related maculopathy.

J M Teikari1, L Laatikainen, J Virtamo, J Haukka, M Rautalahti, K Liesto, D Albanes, P Taylor, O P Heinonen.   

Abstract

PURPOSE: Animal research and observational studies in man suggest a protective effect of antioxidant vitamins in the development of age-related maculopathy (ARM).
METHODS: The ATBC study, a population-based, controlled clinical trial of alpha-tocopherol and beta carotene to prevent lung cancer, took place in Finland between 1984 and 1993. Over 29,000 smoking males aged 50 to 69 years were randomly assigned to alpha-tocopherol (AT; 50 mg/day), beta-carotene (BC; 20 mg/day), both of these, or placebo. We performed an end-of-trial ophthalmological examination on a random sample of 941 participants aged 65 years or more from two of the fourteen study areas, to discover if the five to eight-year intervention with alpha-tocopherol and/or beta-carotene had been associated with a difference in ARM prevalence. Age-related maculopathy was assessed using colour photographs of the macula.
RESULTS: Altogether, 269 cases of ARM were found; there were more cases in the AT group (32%; 75/237), BC group (29%; 68/234), and combined antioxidant group (28%; 73/257) than in the placebo group (25%; 53/213). However, neither substance was significantly associated with the risk of ARM in a logistic regression analysis controlling for possible risk factors.
CONCLUSIONS: No beneficial effect of long-term supplementation with alpha-tocopherol or beta-carotene on the occurrence of ARM was detected among smoking males.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591958     DOI: 10.1034/j.1600-0420.1998.760220.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  17 in total

Review 1.  Macular pigment and age related macular degeneration.

Authors:  S Beatty; M Boulton; D Henson; H H Koh; I J Murray
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

2.  Prevention of age related macular degeneration.

Authors:  Nigel F Hall; Catharine R Gale
Journal:  BMJ       Date:  2002-07-06

3.  Vitamins E and C and medical record-confirmed age-related macular degeneration in a randomized trial of male physicians.

Authors:  William G Christen; Robert J Glynn; Howard D Sesso; Tobias Kurth; Jean Macfadyen; Vadim Bubes; Julie E Buring; Joann E Manson; J Michael Gaziano
Journal:  Ophthalmology       Date:  2012-04-13       Impact factor: 12.079

4.  Macular pigment optical density in the elderly: findings in a large biracial Midsouth population sample.

Authors:  Alessandro Iannaccone; Marco Mura; Kevin T Gallaher; Elizabeth J Johnson; William Andrew Todd; Emily Kenyon; Tarsha L Harris; Tamara Harris; Suzanne Satterfield; Karen C Johnson; Stephen B Kritchevsky
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-04       Impact factor: 4.799

5.  Vitamin E and age-related macular degeneration in a randomized trial of women.

Authors:  William G Christen; Robert J Glynn; Emily Y Chew; Julie E Buring
Journal:  Ophthalmology       Date:  2010-02-13       Impact factor: 12.079

Review 6.  Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.

Authors:  Jennifer R Evans; John G Lawrenson
Journal:  Cochrane Database Syst Rev       Date:  2017-07-30

7.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.

Authors: 
Journal:  Arch Ophthalmol       Date:  2001-10

Review 8.  Nutritional modulation of age-related macular degeneration.

Authors:  Karen A Weikel; Chung-Jung Chiu; Allen Taylor
Journal:  Mol Aspects Med       Date:  2012-04-06

Review 9.  Tocotrienols: Vitamin E beyond tocopherols.

Authors:  Chandan K Sen; Savita Khanna; Sashwati Roy
Journal:  Life Sci       Date:  2006-02-03       Impact factor: 5.037

Review 10.  Age-related macular degeneration: epidemiology and optimal treatment.

Authors:  Morten la Cour; Jens Folke Kiilgaard; Mogens Holst Nissen
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.